$550K
1 filing since 2025 · latest Options filed
Episteme Prognostics, Inc. is a pioneering precision medicine company dedicated to revolutionizing pancreatic cancer diagnosis and treatment. By focusing on the development of groundbreaking diagnostic tests, the company aims to enhance therapeutic decisions, ultimately improving patient outcomes. Their innovative technology leverages epigenetic biomarkers to provide critical insights into treatment responses for patients diagnosed with this challenging disease.
What sets it apart
Episteme Prognostics stands out by utilizing epigenetic biomarkers to create diagnostic tools that predict therapeutic responses in pancreatic cancer, an area with historically limited options.
PancEpistemeDx is a proprietary rapid diagnostic test designed specifically for pancreatic cancer patients. This innovative test evaluates tumor samples to predict how patients will respond to first-line chemotherapy treatments. By identifying responders, this test plays a crucial role in personalizing cancer care.
